+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Translational Systems Medicine and Oral Disease

  • ID: 4753530
  • Book
  • 458 Pages
  • Elsevier Science and Technology
1 of 3

Translational Systems Medicine and Oral Disease bridges the gap between discovery science and clinical oral medicine, providing opportunities for both the scientific and clinical communities to understand how to apply recent findings in cell biology, genomic profiling, and systems medicine to favorably impact the diagnosis, treatment and management of oral diseases. Fully illustrated chapters from leading international contributors explore clinical applications of genomics, proteomics, metabolomics, microbiomics and epigenetics, as well as analytic methods and functional omics in oral medicine. Disease specific chapters detail systems approaches to periodontal disease, salivary gland diseases, oral cancer, bone disease, and autoimmune disease, among others.

In addition, the book emphasizes biological synergisms across disciplines and their translational impact for clinicians, researchers and students in the fields of dentistry, dermatology, gastroenterology, otolaryngology, oncology and primary care.

  • Presents the work of leading international researchers and clinicians who speak on the clinical applications of genomics, proteomics, metabolomics, microbiomics, and epigenetics, as well as analytic methods and functional omics in oral medicine
  • Provides full-color, richly illustrated chapters that examine systems approaches to periodontal disease, salivary gland diseases, oral cancer, bone disease and autoimmune diseases
  • Includes clinical case studies that illustrate examples of oral disease diagnostics and management, highlighting points of key importance for the reader
  • Emphasizes biological synergisms across disciplines and their translational impact for clinicians, researchers, and students in the fields of dentistry, dermatology, gastroenterology, otolaryngology, oncology, and primary care

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Note: Product cover images may vary from those shown
2 of 3

1. Introduction to systems medicine 2. Genomics 3. Proteomics 4. Metabolomics 5. Microbiomics 6. Functional "Omics” for systems medicine 7. Analytic methods for systems medicine 8. Epigenetics and oral diseases 9. Systems medicine in periodontal disease 10. Oral and systemic health 11. Systems medicine in the diseases of the bone 12. Systems medicine and salivary gland diseases 13. Systems medicine and neuropathic oral diseases 14. Systems medicine in oral oncology 15. Systems medicine and autoimmune diseases 16. Stem cells and regenerative medicine 17. Practical considerations applications 18. Conclusion and future directions

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Sonis, Stephen
Dr Sonis's studies on the molecular and cellular pathogenesis of cancer regimen-related tissue damage have established the basis for a mechanistic paradigm for epithelial injury, and have provided treatment targets for biological and pharmaceutical development. Recognizing that genetics plays a role in patient risk for mucositis and other toxicities, Dr. Sonis and his collaborators have used innovative analytics to identify specific pathways that are critical in toxicity development and have applied their findings to form the basis for models of gene-based risk prediction. His broad experience in clinical trial design and innovative end point quality management have been recognized as key components in the success of interventional trials in cancer supportive care.

In addition to his academic appointments, Dr. Sonis is the Chief Scientific Officer of Biomodels; Co-Founder and Chief Scientific Advisor of Inform Genomics; Past president of TRIAD Burden of Illness Studies, a not-for-profit company focusing on the adverse health and economic outcomes of cancer toxicities; co-Founder and Chief Scientific Officer of Primary Endpoint Solutions, LLC, co-Founder and Chairman of BioInsight Diagnostics, and a special government employee of the FDA.

Dr. Sonis has published extensively on the clinical, biological, and health economic aspects of cancer and complications associated with its treatment. He is the author of more than 250 original publications, reviews, and chapters, 10 books and 5 patents.
Villa, Alessandro
Dr. Alessandro Villa is an Associate Surgeon at Brigham and Women's Hospital and Dana-Farber Cancer Institute. He also holds an appointment as Instructor in Oral medicine at the Harvard School of Dental Medicine where he serves as the Program Director for the Oral Medicine Residency Program. Dr. Villa studied dental medicine at the University of Milano, and obtained a PhD from the University of Sassari, Italy. He obtained his Master of Public Health from AT Still University, MO. He completed a surgical residency in oral medicine at Brigham and Women's Hospital/Harvard School of Dental Medicine and a post-doctoral fellowship in cancer epidemiology and genetics at the National Cancer Institute at the National Institutes of Health in Bethesda, MD. Dr. Villa is board certified in Oral Medicine. His clinical interests include the treatment of oral mucosal diseases, salivary gland disorders and oral complications from cancer therapy. Dr. Villa's research interests are focused primarily on potentially malignant disorders of the oral cavity and oral toxicities from cancer treatment.

Dr. Villa has published widely on topics in oral medicine and is the author of over 40 research papers, reviews and chapters. He serves on the editorial boards of both the World Journal of Stomatology and the American Journal of Oral Medicine.
Note: Product cover images may vary from those shown
Adroll
adroll